Nivolumab plus Ipilimumab in Advanced Melanoma

Short summary

Concurrent nivolumab and ipilimumab therapy in advanced melanoma achieved a 40% objective response rate, with 53% of patients responding at maximum doses (1mg/kg nivolumab, 3mg/kg ipilimumab), all showing >=80% tumor reduction.

AI-generated from the title and abstract; the full text is not read.